Impact of Complete Revascularization in the ISCHEMIA Trial

ISCHEMIA Research Group, Gregg W. Stone, Ziad A. Ali, Sean M. O'Brien, Grace Rhodes, Philippe Genereux, Sripal Bangalore, Kreton Mavromatis, Jennifer Horst, Ovidiu Dressler, Kian Keong Poh, Ranjit K. Nath, Nagaraja Moorthy, Adam Witkowski, Sudhanshu K. Dwivedi, Olga Bockeria, Jiyan Chen, Paola E.P. Smanio, Michael H. Picard, Bernard R. ChaitmanDaniel S. Berman, Leslee J. Shaw, William E. Boden, Harvey D. White, Stephen E. Fremes, Yves Rosenberg, Harmony R. Reynolds, John A. Spertus, Judith S. Hochman, David J. Maron, William Boden, Robert Harrington, David Williams, Karen P. Alexander, Jeffrey Berger, Daniel Mark, Christie Ballantyne, Rafael Beyar, Balram Bhargava, Chris Buller, Antonio (Tony) Carvalho, Rafael Diaz, Rolf Doerr, Vladimir Dzavik, Shaun Goodman, Gilbert Gosselin, Rory Hachamovitch, Christian Hamm, Claes Held, Malte Helm, Kurt Huber, Lixin Jiang, Matyas Keltai, Shun Kohsaka, Irene Lang, Renato Lopes, Jose Lopez-Sendon, Aldo Maggioni, John Mancini, C. Noel Bairey Merz, James Min, Eric Peterson, Witold Ruzyllo, Joseph Selvanayagam, Roxy Senior, Tali Sharir, Gabriel Steg, Hanna Szwed, Frans Van de Werf, William Weintraub, Harvey White, Karen Calfas, Mary Ann Champagne, Michael Davidson, Jerome Fleg, Peter A. McCullough, Jonathan Newman, Peter Stone, Philippe Menasche, Stephen Fremes, Robert Guyton, Michael Mack, Fred Mohr, Anupama Rao, Joe Sabik, Oz Shapira, David Taggart, James Tatoulis, Jim Blankenship, Sorin Brener, Antonio Colombo, Bernard de Bruyne, Dean Kereiakes, Thierry Lefevre, Jeffrey Moses, Ken Mahaffey, Salvador Cruz-Flores, Nicholas Danchin, Eli Feen, Mario J. Garcia, Paul Hauptman, Abhay A. Laddu, Eugene Passamani, Ileana L. Pina, Maarten Simoons, Hicham Skali, Kristian Thygesen, David Waters, Patricia Endsley, Gerard Esposito, Jeffrey Kanters, John Pownall, Dimitrios Stournaras, Matthias Friedrich, Raymond Kwong, Dana Oliver, Frank Harrell, Jeffrey Blume, Kerry Lee, Iftikhar Kullo, Bruce McManus, Kristin Newby, David Cohen, Raffaele Bugiardini, Jelena Celutkiene, Jorge Escobedo, Angela Hoye, Radmila Lyubarova, Deirdre Mattina, Jesus Peteiro, Paola Smanio, Dan Berman, Jonathan Leipsic, Roy Mathew, Mandeep Sidhu, Lawrence Friedman, Jeffrey Anderson, Jessica Berg, David DeMets, C. Michael Gibson, Gervasio Lamas, Nicole Deming, Jonathan Himmelfarb, Pamela Ouyang, Pamela Woodard, Samuel Nwosu, Ruth Kirby, Neal Jeffries, Jean E. Denaro, Stephanie Mavromichalis, Kevin Chan, Gia Cobb, Aira Contreras, Diana Cukali, Stephanie Ferket, Andre Gabriel, Antonietta Hansen, Arline Roberts, Anna Naumova, Michelle Chang, Sharder Islam, Graceanne Wayser, Solomon Yakubov, Michelle Yee, Caroline Callison, Isabelle Hogan, Albertina Qelaj, Charlotte Pirro, Kerrie Van Loo, Brianna Wisniewski, Margaret Gilsenan, Bevin Lang, Samaa Mohamed, Shari Esquenazi-Karonika, Patenne Mathews, Vincent Setang, Mark Xavier, Akshay Bagai, Samuel Broderick, Michelle Crowder, Derek Cyr, Jyotsna Garg, Xiangqiong Gu, Lisa Hatch, Anne Heath, Zhen Huang, Jeff Leimberger, Jill Marcus, Courtney Page, Wanda Parker, Wayne Pennachi, Frank Rockhold, Susanna Stevens, Allegra Stone, Omar Thompson, Sheri Ussery, Jennifer White, Mary (Kaye) Williams, Weibing Xing, Songlin Zhu, Kevin Anstrom

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Background: Anatomic complete revascularization (ACR) and functional complete revascularization (FCR) have been associated with reduced death and myocardial infarction (MI) in some prior studies. The impact of complete revascularization (CR) in patients undergoing an invasive (INV) compared with a conservative (CON) management strategy has not been reported. Objectives: Among patients with chronic coronary disease without prior coronary artery bypass grafting randomized to INV vs CON management in the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial, we examined the following: 1) the outcomes of ACR and FCR compared with incomplete revascularization; and 2) the potential impact of achieving CR in all INV patients compared with CON management. Methods: ACR and FCR in the INV group were assessed at an independent core laboratory. Multivariable-adjusted outcomes of CR were examined in INV patients. Inverse probability weighted modeling was then performed to estimate the treatment effect had CR been achieved in all INV patients compared with CON management. Results: ACR and FCR were achieved in 43.4% and 58.4% of 1,824 INV patients. ACR was associated with reduced 4-year rates of cardiovascular death or MI compared with incomplete revascularization. By inverse probability weighted modeling, ACR in all 2,296 INV patients compared with 2,498 CON patients was associated with a lower 4-year rate of cardiovascular death or MI (difference −3.5; 95% CI: −7.2% to 0.0%). In comparison, the event rate difference of cardiovascular death or MI for INV minus CON in the overall ISCHEMIA trial was −2.4%. Results were similar but less pronounced with FCR. Conclusions: The outcomes of an INV strategy may be improved if CR (especially ACR) is achieved.

Original languageEnglish
Pages (from-to)1175-1188
Number of pages14
JournalJournal of the American College of Cardiology
Volume82
Issue number12
DOIs
StatePublished - Sep 19 2023

Keywords

  • complete revascularization
  • coronary artery disease
  • ischemia
  • prognosis
  • revascularization

Fingerprint

Dive into the research topics of 'Impact of Complete Revascularization in the ISCHEMIA Trial'. Together they form a unique fingerprint.

Cite this